American Journal of Cardiology
Volume 108, Issue 3 , Pages 380-384, 1 August 2011

Effect of Peripheral Arterial Disease on Functional and Clinical Outcomes in Patients With Heart Failure (from HF-ACTION)

  • W. Schuyler Jones, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, North Carolina
    • Department of Medicine, Durham VA Medical Center, Durham, North Carolina
    • Corresponding Author InformationCorresponding author: Tel: 919-286-0411, ext. 5214; fax: 919-681-7223
  • ,
  • Robert Clare, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
  • ,
  • Stephen J. Ellis, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
  • ,
  • James S. Mills, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, North Carolina
  • ,
  • David L. Fischman, MD

      Affiliations

    • Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
  • ,
  • William E. Kraus, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, North Carolina
  • ,
  • David J. Whellan, MD

      Affiliations

    • Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
  • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, North Carolina
    • Duke Clinical Research Institute, Durham, North Carolina
  • ,
  • Manesh R. Patel, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, North Carolina
    • Duke Clinical Research Institute, Durham, North Carolina

Received 5 January 2011; received in revised form 16 March 2011; accepted 16 March 2011. published online 12 May 2011.

Patients with peripheral arterial disease (PAD) have lower functional capacity and worse clinical outcomes than age- and gender-matched patients. Few data exist on the relation of PAD to functional and clinical outcomes in patients with heart failure (HF). We sought to compare patients with HF with and without PAD for baseline functional capacity, response to exercise training, and clinical outcomes. HF-ACTION was a randomized controlled trial comparing usual care to structured exercise training plus usual care in patients with HF and an ejection fraction ≤35% and New York Heart Association class II to IV HF symptoms. Cardiopulmonary exercise testing occurred at enrollment, 3 months, and 1 year. Clinical follow-up occurred up to 4 years. Of the 2,331 HF-ACTION patients, 157 (6.8%) had PAD. At baseline, patients with HF and PAD had a shorter exercise duration (8.0 vs 9.8 minutes, p <0.001), lower peak oxygen consumption (12.5 vs 14.6 ml/kg/min, p <0.001), and shorter 6-minute walking distance (306 vs 371 m, p <0.001) compared to patients with HF without PAD. At 3 months patients with HF and PAD had less improvement on cardiopulmonary exercise testing (exercise duration 0.5 vs 1.1 minutes, p = 0.002; mean change in peak oxygen consumption 0.1 vs 0.6 ml/kg/min, p = 0.04) compared to patients with HF without PAD. PAD was an independent predictor of all-cause death or hospitalization (hazard ratio 1.31, 95% confidence interval 1.06 to 1.62, p = 0.011). Patients with PAD and HF had deceased baseline exercise capacity and decreased response to exercise training. In conclusion, PAD is an independent predictor of all-cause death or hospitalization in patients with HF.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by Grant 5U01HL063747 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland to Dr. O'Connor at Duke University and Duke Clinical Research Institute (coordinating center).

PII: S0002-9149(11)01352-X

doi:10.1016/j.amjcard.2011.03.057

American Journal of Cardiology
Volume 108, Issue 3 , Pages 380-384, 1 August 2011